open access
Progression-free survival as a reliable criterion for assessment of the value of systemic anticancer therapy
open access
Abstract
Hazards related with the choice of progression-free survival as a criterion for assessment of the value of systemic anticancer therapy are presented in this study. The arguments for overall survival as reliable end-point in clinical trials in oncology are discussed.
Abstract
Hazards related with the choice of progression-free survival as a criterion for assessment of the value of systemic anticancer therapy are presented in this study. The arguments for overall survival as reliable end-point in clinical trials in oncology are discussed.
About this articleTitle
Progression-free survival as a reliable criterion for assessment of the value of systemic anticancer therapy
Journal
Nowotwory. Journal of Oncology
Issue
Pages
68-69
Published online
2016-04-07
Page views
665
Article views/downloads
4077
DOI
Bibliographic record
Nowotwory. Journal of Oncology 2016;66(1):68-69.
Authors
Piotr Rutkowski